MYGN Stock Recent News
MYGN LATEST HEADLINES
Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.
Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.
Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Investors are optimistic about Myriad Genetics (MYGN) on recent partnerships and growth in testing volumes.
Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Elizabeth Koslosky - Goldman Sachs Andrew Cooper - Raymond James Daniel Sammarco - TD Cowen Jack Meehan - Nephron Research Wolf Chanoff - Bank of America Matt Scalo Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes.